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Chlamydia trachomatis causes vaginal discharge in females, urethritis in males and 
lymphogranuloma venereum (LGV) in both males and females. In South Africa C. trachomatis 
infection is treated with a 1g dose of azithromycin as part of the syndromic management regime.  
Under this regime, patients presenting with a particular set of symptoms are treated using a cocktail 
of drugs which treat the most common causes of that particular syndrome without performing 
laboratory diagnosis or susceptibility tests.  This includes treatment with 250mg of ceftriaxone and 
2g of metroniadazole.  For this system to be effective, periodic surveillance needs to take place to 
determine which organisms are circulating in the population and their susceptibility to the 
recommended antimicrobial agents.  In this study we determined the minimum inhibitory 




Cervical specimens were collected from patients presenting with genital discharge and screened 
by the BD ProbeTec™ ET assay . Specimens that tested positive were cultured. C. trachomatis 
was grown from four specimens. The MICs of eight antimicrobial agents were determined for a 
total of 11 C. trachomatis isolates using either immunofluorescence or real time PCR.  For both 
methods McCoy cells were infected with C. trachomatis with centrifugation.  After centrifugation 




antimicrobial agent and incubated for 48 hours.  After 48 hours, cell culture monolayers were 
either fixed with 95% ethanol and stained with the MicroTrak C. trachomatis Culture 
Confirmation Kit for inclusion identification using a fluorescent microscope, or lysed with 
TriSURE for RNA extraction followed by cDNA conversion and detection using real time PCR.  
The antimicrobial agents used were tetracyclines (tetracycline, doxycycline and minocycline), 
macrolides (azithromycin, erythromycin and clarithromycin), a fluoroquinolone (ciprofloxacin) 
and a glycycline (tigecycline).  The C. trachomatis isolates included 5 isolates collected from 
discharge patients and 3 isolates collected from LGV patients in South Africa, as well as three 
LGV reference strains available from the ATCC. 
 
Results 
All eight of the antimicrobial agents tested had an inhibitory effect on all C. trachomatis isolates 
used. For the tetracyclines, MICs were ≤ 0.125, 0.031-0.063 and 0.125 mg/L for tetracycline, 
doxycycline and minocycline respectively . For the macrolides the MICs were 0.125-0.5, 0.125 
and ≤ 0.062 mg/L for azithromycin, erythromycin and clarithromycin respectively. The MIC of 
ciprofloxacin was 0.5 – 1 mg/L for the isolates tested.  The MIC of tigecycline ranged from 0.125 
to < 0.0625 mg/L for the isolates tested. These MICs are in line with previous published MICs.  
 
Conclusion 
All eight of the antimicrobial agents tested had an inhibitory effect on all C. trachomatis isolates 
used, including azithromycin, the current drug of choice in South Africa.  However azithromycin 
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CHAPTER 1 - INTRODUCTION 
 
Sexually transmitted diseases (STDs) are of pandemic proportions globally and prevalence figures 
are rising (CDC, 2015).  Infections caused by the genital biovar of Chlamydia trachomatis 
contribute greatly to this pandemic in all parts of the world (WHO, 2008).  In 2012, global 
prevalence of C.trachomatis infections was found to be 4.2% in women and 2.7% in men ( 
Newman et al, 2015).  The organism causes urethritis and a complication known as epididymitis 
in men as well as urethritis and cervicitis in women.  In women the infection can be complicated 
by ectopic pregnancies, pelvic inflammatory disease and peri-hepatitis (Karnath, 2009).  
Lymphogranuloma venereum is an STD caused by a different biovar of C. trachomatis. Several 
different tests can be applied for the laboratory diagnosis of C. trachomatis infections.  However 
nucleic acid amplification tests are the most commonly used, but for many less-resourced settings 
including South Africa, these commercial NAATs are too expensive for wide use (Papp et al, 
2014).  Use of NAATs are also too demanding in terms of laboratory commitment.  In South 
Africa, STDs are treated syndromically according nationally formulated guidelines (SA 
Department of Health, 2015). 
Amongst the drugs used in syndromic treatment, azithromycin, a macrolide is effective against 
C.trachomatis infections (Department of health 2015).  Other drugs can also be used and these 
include the tetracyclines, other macrolides, fluoroquinolones and glycyclines (Somani et al, 2000).  
Due to extensive antibiotic use, drug resistance is bound to occur (Somani et al, 2000). No response 
to treatment is an indicator of resistance but, as with all STDs, this can also be the result of early 
reinfection.  It is essential to carry out regular susceptibility testing to ensure that the given 
antibiotic treatment regimens are working correctly.  However, being an obligate intra-cellular 




organisms. Therefore, studies on drug susceptibility of C. trachomatis are rare.    Although 
infections with the genital and LGV biovar are prevalent in South Africa, susceptibility testing on 
clinical isolates has not been done.  
The aim of this project is to determine the resistance profile of C. trachomatis isolates from patients 
in KwaZulu-Natal, South Africa to azithromycin and other antimicrobial drugs that can potentially 
be used to treat chlamydia infections.   
Susceptibility testing was performed in cell culture and both immunofluorescence and real time 
PCR were used to establish growth inhibition.  C. trachomatis L2, strain 434 was used as the 
reference strain since MIC values of that strain have been published in the literature (Table 1).  
 
Table.1: Published MICs of L2 strain 434 and  
Antibiotic MIC L2 MIC E Reference 
    
Tetracycline 0.51 0.26 Walsh et al 
Minocycline 0.031 0.016 Miyashita et al 
Doxycycline 0.031 0.063 Miyashita et al 
Tigecycline 0.125 No info  Townsend et al 
Clarithromycin 0.031 0.031 Miyashita et al 
Azithromycin 0.125 0.125 Miyashita et al 
Erythromycin 0.125 0.125 Miyashita et al 













Sexually transmitted diseases (STDs) are a major public health problem globally (WHO, 2001). 
SomeSTDs, including those caused by Chlamydia trachomatis, may increase the transmission of 
HIV (WHO, 2001).  Therefore effective management and prevention of STDs will help to reduce 
the incidence of HIV (WHO, 2001). 
The highest prevalence of STDs occurs in developing countries (WHO, 2001), in particular in the 
young adult population (WHO, 2001).  In 2008, there were 498.9 million new cases of STDs 
globally and 105.7 million of these cases were caused by C. trachomatis (WHO, 2008).  High 
incidence rates of STDs continue to pose a threat to the social and economic status of countries 
greatly affected by this pandemic (Stephen and Shelagh, 2004).  C. trachomatis infection is one of 
the most common STDs in both male and female (Sciara, 1997).  Chlamydia prevalence and 
incidence rates are higher in females than males (WHO, 2005). According to a STD surveillance 
study carried out in the USA, a notable increase in chlamydia prevalence rates is seen in all regions 
between 2002 and 2011 (CDC, 2011).  
In South Africa, contrary to the WHO report (2005) chlamydia infections are detected in 11% of 
women who present with vaginal discharge syndrome (Moodley et al 2002) and 16% of male 
patients who present with urethritis (Sturm et al 2004).  Chlamydia infection accounts for 13.6% 







2.2 Clinical Manifestations 
 
C. trachomatis is a bacterial pathogen which is usually classified into two biovars, the oculogenital 
(OG) biovar and the lymphogranuloma venereum (LGV) biovar (Harris et al, 2012).  However, 
within the OG biovar, some isolates are oculo-tropic, while others have a higher tropism for genital 
tissue, indicating that this OG biovar should be further subdivided into two groups which reflect 
disease tropisms which are based on genetic differences (Harris et al, 2012).  C. trachomatis is 
also classified into 18 serovars which reflect differences in the Major Outer Membrane Protein 
(MOMP) (Harris et al, 2012).  The oculo-tropic strains (serovars A-C) within the OG biovar cause 
trachoma (Cross et al, 1999) while the genito-tropic strains (serovars D-K) within the OG biovar 
cause genital discharge disease (Bebear and Barbeyrac, 2008).  Strains of the LGV biovar (serovars 
L1-L3) cause lymphogranuloma venereum (LGV).  
As with most STDs, a large percentage of genital chlamydia infections are asymptomatic and go 
unnoticed (Agrawal et al 2009).  As a result, the infected person does not seek treatment and 
becomes a reservoir of infection within the community (Agrawal et al 2009).   In men who test 
positive for C.trachomatis, symptomatic urethritis occurs in 15 to 55 % but this is considerably 
lower in older men (Miller, 2006).   Untreated infections in men may lead to a complication known 
as epididymis while in females this can lead to ectopic pregnancy and pelvic inflammatory disease 




(Miller, 2006).  Untreated chlamydia infections may cause Reiter syndrome, which is a reactive 
arthritis.  The prevalence of this manifestation is higher in women than in men (Miller, 2006). 
Strains of the LGV biovar, namely L1, L2 and L3 cause a more invasive disease called LGV which 
begins as a genital ulcer.  The chlamydia migrate to the inguinal lymph nodes (Cross et al, 1999) 
resulting in tender inguinal and/or femoral lymphadenopathy (CDC, 2015).  The clinical 
manifestation of LGV which develops in the MSM population and in women due to rectal exposure 
is called proctocolitis (CDC, 2015) and is accompanied by pelvic lymphadenopathy.  Treatment 
of LGV includes the use of doxycycline, azithromycin or erythromycin (SA Department of Health, 
2015).     
 
2.3 Biology of the organism and lifecycle 
 
C. trachomatis is an obligate intracellular bacterial pathogen with a unique biphasic life cycle 
(Cross et al, 1999).  C. trachomatis exists in two forms, an extracellular form called the elementary 
body (EB) and an intracellular form called the reticulate body (RB) (Mpiga and Ravaoarinoro, 
2006).  The EBs are metabolically inactive, osmotically stable and are able to infect cells. The RBs 
are metabolically active, osmotically fragile and responsible for replication once the organism has 
entered a susceptible host cell (Mpiga and Ravaoarinoro, 2006).  The cell wall of C. trachomatis 
contains inner and outer membranes which is typical of Gram negative bacteria. However no 
peptidoglycan layer is present (Mpiga and Ravaoarinoro, 2006).  Disulphide-cross linked proteins 




Once a susceptible host cell has become infected, the EB differentiates into a RB which is 
internalized in a vacuole formed by the phagosome, and escapes phagolysosomal fusion (Mpiga 
and Ravaoarinoro, 2006).  The RB is metabolically active and divides by binary fission (Mpiga 
and Ravaoarinoro, 2006).  The RB then recondenses to form EB which are released from the cell 
via exocytosis (Mpiga and Ravaoarinoro, 2006).  C. trachomatis infections may go unnoticed 
because the organism is thought to have a metabolically less active state, which it uses to escape 
from the immune system allowing the bacteria to multiply (Mpiga and Ravaoarinoro, 2006).  
 
2.4 Pathogenesis of infection 
 
Epithelial cells are the primary target cells for C. trachomatis infection (Darville and Hiltke, 2010).  
Upon primary infection of epithelial cells, EBs trigger the secretion of cytokines which recruit 
neutrophils to the site of infection (Rasmussen et al, 1997). Neutrophils are capable of killing 
extra-cellular EBs (Darville and Hiltke, 2010). T-cells accumulate at a later stage and play a role 
in clearing the infection (Ramsey and Rank, 1991), but chlamydia-specific immune cells are not 
able to prevent new infections (Bebear and Barbeyrac, 2008).  Instead of having a protective effect 
they release chemokines at the site of infection, which cause tissue damage brought about by 
proteases, clotting factors and tissue growth factors (Molano et al, 2005).  Inflammation and 
fibrosis occur as a result of infection (Bebear and Barbeyrac, 2008).  Persistent forms of C. 
trachomatis may also develop as a result of antibiotic treatment, nutrient depletion and cytokines 
(Ward, 1999).  The cell mediated immune response triggers the release of interferon-, resulting 




response (Ward, 1999).  A marker used to diagnose chronic C. trachomatis infection is the 
presence of anti-Hsp antibodies (Dean et al, 2000). 
 
2.5 Laboratory diagnosis 
 
The type of specimen collected varies depending on the laboratory diagnostic technique to be 
performed (Bebear and Barbeyrac, 2008).  When using modern NAATs for diagnosis, specimens 
such as urethral swabs and cervical swabs are more sensitive than tests done on non-invasive 
specimens which are usually self-collected, such as vulvovaginal swabs, penile swabs, anal swabs 
and first void urine specimens (Michel et al, 2007).  Although these non-invasive specimens are 
easier to obtain and cause less discomfort to the patient, they contain a high bacterial load with 
commensal species and are not suitable for cell culture which is required if susceptibility testing 
is to be performed (Michel et al, 2007).  Methods of diagnosis include cell culture, antigen-based 
detection methods, nucleic acid hybridization tests and nucleic acid amplification technologies 
(Bebear and Barbeyrac, 2008).  
Cell culture techniques are laborious but have high specificity (Black, 1997).   Cell culture has a 
long turnaround time and routine use is not recommended due to its lack of sensitivity (Black, 
1997).  Specimens need to be placed in liquid transport media immediately after collection and 
same day refrigeration and transport to the laboratory is required (Black, 1997).  However, cell 
culture is highly recommended for antimicrobial susceptibility testing (Bebear and Barbeyrac, 
2008).  Other methods of detection include direct fluorescent staining and enzyme immunoassay 




of specimens need to be processed (Michel et al, 2006).  Enzyme immunoassay has a higher 
sensitivity than cell culture, but it can also produce false positives (Michel et al, 2006).  DNA 
probing is a molecular test which can be used for diagnosis and is more sensitive than cell culture 
methods but cannot be used with non-invasive specimens (Schachter et al, 2005).  Nucleic acid 
amplification tests (NAATs) are highly sensitive and specific (Leber et al, 2006).  Non-invasive 
and invasive specimens can be processed by NAATs (Schachter et al, 2006).   
 
2.6 Treatment and prevention 
 
There are several antimicrobial agents which can be used to treat C. trachomatis infection and the 
best choice depends on the type of infection, site of infection, age of the patient, as well as 
pregnancy status in women (Miller, 2006).   
In South Africa STDs are currently managed syndromically (Altini and Coetzee, 2003).   
Identification of the STD syndrome is based on symptoms and observations during examination 
(SA Department of Health, 2015).  The syndrome is then treated with a combination of drugs 
which are effective against common causes of the syndrome (Altini and Coetzee, 2003).  This 
enables health care providers to diagnose and treat patients on the same day without waiting for a 
laboratory diagnosis (Altini and Coetzee, 2003).  
In our setting, C. trachomatis is a bacterial pathogen which is responsible for the development of 
genital ulcers with lymphadenopathy (Sturm et al, 2005), genital discharge disease (Bebear and 
Barbeyrac, 2009) and trachoma (Cross et al, 1999) in men and women. Syndromic management 
of genital discharge disease includes the use of ceftriaxone, azithromycin and metronidazole, while 




acyclovir and azithromycin (SA Department of Health, 2015).  Amongst these drugs, azithromycin 
is used to treat chlamydial infections (Frye et al 2008). 
Tetracyclines, macrolides and fluoroquinolones are effective in treatment of chlamydia infections 
(Somani et al, 2000).  Tetracyclines have been used as standard treatment for non-specific genital 
infections as well as chlamydia infections (Ridgway, 1997).  Treatment of chlamydia infection 
usually consists of a 7-day regimen of doxycycline (Frye et al 2008).  The macrolides, 
azithromycin, erythromycin and clarithromycin can also be used as an alternative treatment for 
chlamydial infections in patients who develop adverse effects to doxycycline but doxycycline has 
a higher cure rate (Frye et al 2008).  Azithromycin is a safe drug which can be used during 
pregnancy, but is more expensive than treatment with doxycycline (Frye et al 2008).  
Fluoroquinolones have a broad spectrum of antimicrobial activity (King et al, 2000).   
Use of these antibiotics are usually 90-100% effective, however recurring infection is inevitable 
due to large numbers of asymptomatic infections in the population (Mpiga and Ravaoarinoro, 
2006).   Antibiotic treatment failure may occur due to poor compliance of patients to their treatment 
regime (Mpiga and Ravaoarinoro, 2006).  Therapy failure may also be due to chlamydial resistance 
(Somani et al, 2000). 
 Prevention of STDs is a high priority and the CDC has set guidelines on concepts for prevention 
(Miller, 2006).  These guidelines include education on safe sexual behavior, awareness of 
symptomatic and asymptomatic infection, availability of diagnosis and treatment facilities, 
counselling services for both infected persons as well as their partners and also vaccines should be 




in controlling and reducing prevalence, however no vaccines are available for the prevention of 
C. trachomatis infections (Mpiga and Ravaoarinoro, 2006).  
 
 
2.7 Antimicrobial agents 
 
Previously macrolides were the drug of choice for treatment of C.trachomatis infections, however 
it has more recently been discovered that tetracyclines are more effective (Handsfield HH, 2011).  
Quinolones can also be used in treatment as well as the glycycline group of antimicrobial agents 
(Somani et al, 2000).  Table 2 below shows the published MIC values for reference strain L2 434 






















Table 2: Chemical structure of the antimicrobial agents used in this study 










                              




























































Tetracyclines are broad spectrum antimicrobial agents which are effective against Gram-positive 
and Gram-negative bacteria, as well as some protozoa (Nelson and Levy, 1999). They are used as 
growth promotors in animal feeds, for malaria prophylaxis and for treatment of infections (Nelson 
and Levy, 1999).  Tetracyclines are useful because they are low in toxicity, relatively inexpensive 
and are easily absorbed (Michalova et al, 2004). 
The structure common to all tetracyclines is a linear fused tetracyclic nucleus (table 2) which 
serves as a site of attachment for a variety of functional groups ( Mitscher, 1978) .  Substitutions 
on the nucleus rings enable variation of tetracyclines to be possible, thus resulting in different 
tetracyclines for clinical use (Rogalski, 1985).   There are 11 different types of tetracyclines that 
are used clinically (Chopra and Roberts, 2001) however only 3 were used in this study namely; 
tetracycline, minocycline and doxycyline.   
The mechanism of action of tetracylines is inhibition of protein synthesis by preventing the 
interaction of the aminoacyl tRNAs with ribosomes (Michalova et al, 2004).  In Gram negatives 
such as C. trachomatis, tetracyclines bind to a positively charged cation and enter the bacterial cell 
through the pores in the outer membrane (Chopra et al, 1992).  Once in the periplasm, the 
tetracycline-cation complex dissociates which allows the tetracycline to enter the lipid bilayers of 
the inner membrane (Schnappinger and Hilton, 1996).  The process of entry of tetracyclines into 
the cytoplasm is energy dependent and once the tetracycline binds to the ribosome, this binding 
becomes irreversible resulting in its bacteriostatic effect (Chopra et al, 1992).  
Emerging resistance to tetracyclines is becoming a hurdle in medical treatment (Chopra and 




that the use of tetracyclines as growth promotors in animal feed may have also contributed to the 
resistance emerging in human pathogens (Chopra and Roberts, 2001).  There are two different 
types of genes responsible for causing tetracycline resistance through acquisition of plasmids 
(Levy et al, 1999).  Efflux pumps are also responsible for resistance to tetracyclines, however these 
pumps are not effective against macrolides and glycyclines (Chopra et al, 1992).  Production of 
ribosomal protection proteins is another mechanism of resistance (Sanchez-Pescador et al, 1988) 




Glycyclines are a new class of antimicrobial agent which have been developed due to increasing 
resistance to tetracyclines (Sum et al, 1998).  Glycyclines are structurally similar to tetracyclines 
in that they contain the same central four ring carboxylic skeleton however they differ by the 
presence of an N-alkyl-glycylamido group on the D ring (table 2) which enables these compounds 
to have a broader spectrum of activity (Chopra, 2001).   
Glycycline antibiotics are known to be effective against Gram positive and Gram negative 
organisms, including those bacteria resistant to tetracyclines (Sum et al, 1998). It has been shown 
in vitro that tigecycline is effective against many organisms (Jones et al, 2004).  The use of 
tigecycline proves very advantageous as it is active against bacteria which are resistant to other 
antibiotics (Chopra, 2001).  Tigecycline is able to overcome de-activation mechanisms common 
to the tetracyclines. Therefore tetracycline resistance is overcome by use of tigecycline (Bauer et 
al, 2004). The modification in structure of tigecycline enables it to bypass resistance mechanisms 




ribosomal protection (Zhanel et al, 2004).  These resistance mechanisms are avoided by tigecycline 





Macrolides are a group of antimicrobial agents used commonly to treat Gram-positive bacterial 
infections as well as some infections caused by Gram negative species such as Bordetella pertussis 
and Campylobacter, Chlamydia, Helicobacter and Legionella species (Gaynor and Mankin, 2003).  
Currently there are 5 different natural macrolide antimicrobial agents and 7 semisynthetic 
macrolides available (Mazzei et al, 1993).  The macrolides used in this study are erythromycin 
which is a natural macrolide as well as clarithromycin and azithromycin which are semisynthetic 
macrolides.  The structure common to all macrolides is the lactone ring which usually contains 
between 12 to 16 atoms (Mazzei et al, 1993).   Macrolides differ in the number of rings per 
molecule as well as the different substitution groups present on the atoms which are shown in table 
2 (Briskier et al, 1986).   
Erythromycin was the first macrolide employed for clinical use, however acid instability of the 
drug led to the production of the newer macrolides clarithromycin and azithromycin (Gaynor and 
Mankin, 2003).  Macrolides inhibit protein synthesis by binding to the ribosome, which leads to 
inhibition of the formation of peptide bonds (Hansen et al, 2002) by releasing peptidyl-tRNA. This 
disrupts protein synthesis (Menninger JR, 1995) by compromising assembly of the ribosome 




Resistance to macrolides can occur either by modifying the target site of the drug or excreting the 






 Quinolones are recognized by their heterocycles and bicyclic core structure as seen in table 2 (Hu 
et al, 2003).  Fluoroquinolones are derivatives of quinolones because of fluoridation of the 
quinolone molecule at C6 (Paton and Reeves, 1988).  Second generation fluoroquinolones are 
norfloxacin and ciprofloxacin (Paton and Reeves, 1988), third generation fluoroquinolones include 
levofloxacin, gatifloxacin and moxifloxacin (Barrett, 2000), the fourth generation fluoroquinolone 
developed isknown as gemifloxacin (Lowe and Lamb, 2000).   
Fluoroquinolonesare broad spectrum antibiotics and the most commonly used fluoroquinolone is 
ciprofloxacin (Fabrega et al, 2009).  Fluoroquinolones are effective against a wide range of Gram 
positive and Gram negative bacteria (Hawkey, 2003).  The primary target in Gram negative 
bacteria is DNA gyrase and the primary target in Gram positive bacteria is topoisomerase IV 
(Drlica and Zhao, 1997).  DNA gyrase is responsible for the separation and re-binding of DNA 
strands during replication (Hawkey, 2003).  The activity of topoisomerase IV is similar to that of 
DNA gyrase, however its primary function is to break the link of newly replicated daughter 
chromosomes as well as decantation (Kato et al, 1990). Quinolones thereby inhibit DNA synthesis 
by binding to DNA gyrase or DNA topoisomerase complexes (Khodursky and Cozzarelli, 1998). 




Upon breaking of DNA strands caused by the enzyme, the strands are unable to ligate again since 
the quinolone has bonded to the DNA enzyme complex, thus inhibiting DNA synthesis 
(Khodursky and Cozzarelli, 1998).  When quinolones bind to gyrase –DNA complexes, replication 
stops at a fast rate since gyrase binds to DNA ahead of the replication fork (Khodursky and 
Cozzarelli, 1998).  In organisms where quinolones bind to topoisomerase-DNA complexes, DNA 
synthesis is inhibited at a slower rate since topoisomerase binds to the DNA behind the replication 
fork (Khodursky and Cozzarelli, 1998).  High concentrations of quinolones can be used to kill 
cells rather than to inhibit growth (Zhao et al, 1997).  Resistance to quinolones are known to arise 
and are due to mutations in the genes that encode gyrase and topoisomerase IV (Hoshino et al, 
1994).  Structural changes in the organism are also responsible for resistance, namely changes in 
the porins, which effects entry into the cell (Nikaido, 1998).  
 
2.8. Susceptibility testing 
 
Because C. trachomatis is an obligate intracellular organism, traditional methods of antimicrobial 
susceptibility testing cannot be used (Cross et al, 1999).  As such there are no EUCAST or CLSI 
guidelines for this and no recommended break points.  When susceptibility testing of C. 
trachomatis is required, a combination of cell culture and either immunofluorescence or a 
molecular method is usually used since there is no standardized methodology or interpretation of 
results available (Suchland et al, 2002).  A previous study conducted for antimicrobial 
susceptibility testing of C. trachomatis showed that determining the end point by reverse 
transcriptase PCR may be useful due to its sensitivity (Cross et al, 1999).  This study was 




et al, 1999).  Immunofluorescence is rather subjective and a study conducted by Peuchant et al 
showed that using real time PCR for susceptibility testing is more reliable and objective.   
 
2.9 Drug resistance in Chlamydia trachomatis 
 
There are two different types of resistance: in vivo or clinical resistance and in vitro or laboratory 
resistance.  Since determination of in vitro resistance of C. trachomatis is hampered by the need 
for culture and the complicated techniques involved in susceptibility testing of intra-cellular 
organisms (2.8), reports on in vitro resistance are scarce.  
Resistance of chlamydia infections to antimicrobial treatment has been reported in Wyoming USA 
in two patients in which clinical treatment with azithromycin failed as well as one contact of one 
of these patients. In vitro susceptibility confirmed resistance to azithromycin, doxycycline and 
ofloxacin in all three isolates (Somani et al, 2000).   
Tetracycline resistance has been reported in USA as a result of clinical treatment failure (O’Neill 
et al, 2013).  These “resistant” strains were further studied and found to be sensitive to tetracycline 
in vitro indicating that the reported treatment failure may have been due to re-infection or poor 
patient compliance (O’Neill et al, 2013).  Repeat infections following treatment of C. trachomatis 
is common (Hockinget al, 2013).   
In vitro tetracycline resistance has also been reported in Indianapolis, USA (Jones et al, 1990). 
This study incorporated five different chlamydia isolates which were reported to have clinical 




was found that isolates resistant to tetracyclines were also resistant to doxycycline and 
erythromycin. 
Resistance was also reported in Russia which entailed a study comprising of six chlamydia isolates.   
These isolates were tested against antimicrobial agents and it was found that four of these isolates 
were resistant to azithromycin and erythromycin (Misyurina et al, 2003).   
In bacteria resistance to antimicrobial agents can occur by enzymatic degradation of antibacterial 
drugs, alteration of bacterial molecules that are antimicrobial targets and changes in membrane 
permeability (Dever and Dermody, 1991).  When presented with adverse circumstances, 
organisms adapt for survival and can do so via genetic mutations (Woodford and Ellington, 2007).   
Although resistance has been reported as mentioned above, a compilation of other studies show 
azithromycin to be effective against 97% of infections and 98% efficacy for doxycyline 
(Handsfield HH, 2011).  
In the United States of America (USA) and other parts of the world where the prevalence of C. 
trachomatis is high, many patients experience “recurrent” infections (Munday et al, 1995).  This 
is either due to re-infection or an infection which persists after treatment (Munday et al, 1995).  
Studies of young women presenting with genital infection in the United Kingdom (UK) 
(Lamontagne et al, 2007) and the USA (Batteiger et al, 2010) found that 30% and 34% tested 
positive for C. trachomatis 6 months and 3 months after treatment. 
The first line drugs for treatment of chlamydial infections, tetracyclines and azithromycin, are 
usually effective unless a change in the organism’s life cycle brings about persistence (Sandoz and 
Rockey, 2010).  It is this persistence of the organism which is believed to be associated with 




The problem is further compounded by co-infection with other bacteria (Stamm et al, 1984).  In 
patients presenting with chlamydia infection, co-infection with Neisseria gonorrhoea or 
Treponema pallidum is not uncommon and this complicates treatment (Stamm et al, 1984).   
 
2.9.1. Genetics of resistance  
 
C. trachomatis displays heterotypic resistance.  This implies that some isolates within the 
chlamydial population may be susceptible, while others are resistant to the same antimicrobial 
agents (Somani et al, 2000).  Chlamydia contain a unique phylogenetic and genetic lineage, with 
their genomes containing distinct areas with conserved regions (Sandoz and Rockey, 2010).   
 
In most bacteria horizontal gene transfer is an important means to gain resistance genes as a 
survival mechanism (O’Neill et al, 2013).  However, the metabolically active form of C. 
trachomatis, the RB, remains inside a susceptible host cell, therefore acquisition of new genes via 
horizontal gene transfer from other bacteria is unlikely (O’Neill et al, 2013).  Instead resistance is 
usually acquired through point mutations and resistant strains are capable of sharing these genes 
via horizontal gene transfer between each other or homologous recombination, (Sandoz and 
Rockey, 2010).   
 
Beta-lactam drugs are effective against T. pallidum and N. gonorrhoeae, however exposure of C. 
trachomatis to these antibiotics in vitro causes changes in the structure of the RB (Stamm, 2010).  
The RB stops cell division, but once the β-lactam drug is removed, cell division continues and EB 




chlamydia RNA and DNA, which is evident of some type of resistance in chlamydia (Gerard et al, 
2004).  C. trachomatis causing secondary infections such as reactive arthritis and chronic 
prostatitis are known to consist of RBs which differ from the normal RBs (Gerard et al, 2009).   
   
Emerging resistance to antimicrobial drugs is a major threat to public health (Somani et al 2000).  
No current standard is available for antimicrobial susceptibility testing of                     C. trachomatis 
in South Africa.  The development and utilization of a test for drug susceptibility of C. trachomatis 
would indicate whether or not drug resistance is emerging in our setting and could pave the way 








CHAPTER 3 - METHODOLOGY 
 
3.1. Study participants and specimen collection 
 
Study participants were recruited from the Boom Street Clinic in Pietermaritzburg from May 2014 




were collected from females 18 years and older presenting with either vaginal discharge syndrome 
(VDS) or a genital ulcer and from males 18 years and older presenting with either urethritis 
syndrome or a genital ulcer.  The study was approved by the Biomedical Research Ethics 
Committee of the University of KwaZulu Natal (BE220/13) as well as the KZN Department of 
Health and management at the clinics. 
Specimens were collected by a study nurse.  In females presenting with vaginal discharge 
syndrome, the cervix was visualised with the aid of a speculum, excess mucus was wiped off the 
cervical os and an endocervical specimen was collected using a Dacron swab.  The swab was 
inserted for approximately 3 cm and withdrawn under gentle rotation to collect discharge and 
epithelial cells.  In males presenting with urethritis syndrome, urethral specimens were collected. 
The urethral opening was cleaned using gauze and saline.  A urethral Dacron swab on a flexible 
wire shaft was inserted approximately 3 cm into the urethra and withdrawn while rotating.  Genital 
ulcer specimens were collected the same way for males and females.  The ulcer was cleaned with 
a dry gauze to remove debris.  A Dacron swab was rolled over the base and under the edges of the 
ulcer to collect exudate. 
 
Two swabs were collected from each patient, one for Chlamydia trachomatis screening by PCR, 
and one for C. trachomatis culture.  The swab that was used for culture was submerged in 1 ml 
chlamydia transport medium, placed on ice and transported to the laboratory for processing on the 
same day. The swab that was used for screening was placed in PBS and kept in the fridge at 2-8°C 






3.2 Screening for Chlamydia trachomatis 
 
Cervical and urethral specimens were screened for chlamydia on the day of collection using the 
BD ProbeTec™ ET C. trachomatis NA amplification assay (NAAT) processed on the BD Viper™ 
System. This system detects chlamydia positive reactions by using strand displacement 
amplification and fluorescent energy transfer.  The L2 434 (ATCC® VR-902B™) reference strain 
was used as a positive control.   
 
Ulcer specimens were screened for chlamydia using an in house strand displacement amplification 
method(Sturm et al, 2005).  These specimens were batched and processed within 1 week.  All 
ulcer specimens were cultured on the day of collection without waiting for PCR results. 
 
 
3.3 Cell culture 
 
HeLa cells, used at the start of the study, were grown in EMEM supplemented with 10% heat 
inactivated fetal bovine serum (FBS).  Cells were incubated at 37°C in 5% C02 and grown until 
90% confluency.  The cells were then trypsinised and stored in freezing fluid at -80°C.  When 
needed, cells were retrieved from the freezer and grown in EMEM supplemented with 10% FBS 
until 80-90% confluent after which they were trypsinised and split into multiple flasks to obtain a 
higher yield of cells sufficient for carrying out experiments. A total of 11 NAAT positive 
specimens were inoculated and incubated in the HeLa cells of which none grew.  Since the NAAT 
positive clinical isolates failed to grow in the HeLa cell line, McCoy cells were used as an 
alternative to process and culture clinical isolates.  McCoy cells were grown in the same manner 







3.4 Chlamydia trachomatis 
 
3.4.1 Isolation of Chlamydia trachomatis from clinical specimens 
 
In order to grow C. trachomatis from clinical specimens, HeLa and later McCoy cells were seeded into 
Trac vials containing glass coverslips.  The seeding density was adjusted to ensure that there were 
Trac vials with 80 % confluent cells ready for infection on each day of specimen collection. Before 
inoculation, the cell culture media was removed and replaced with 0.5 ml chlamydia growth media 
(CGM).  CGM consists of EMEM (BioWhittakerTM) with Earle’s Balanced Salt Solution (EBSS), 
nonessential amino acids (NEAA) and sodium pyruvate. CGM was further enriched to yield final 
concentrations of the following: 10 mM HEPES, 2 mM L-glutamine, amikacin (25 g / ml), 
amphotericin B (5 g / ml), gentamycin (5g / ml), glucose (5.4 mg / ml) and 10% FBS. 
Three sterile glass beads were added to the tubes containing chlamydia transport medium and the 
swab.  This was vortexed for 2 minutes with the swab still in place to release the specimen from 
the Dacron.  Sterile forceps were used to express fluid from the swab by pressing it against the 
side of the tube thereafter the swab was discarded.  
Specimens were inoculated onto 80% confluent McCoy cell monolayers grown in Trak vials.  Two 
Trak vials were inoculated with each specimen: 300 µl each.  The Trak vials were then centrifuged 
at 2500 × g at 30°C for one hour and incubated at 37°C for 2 hours.  After this incubation step, the 
media was removed and replaced with 2 ml fresh CGM and incubated at 37°C for 4 days.  A 




as well as a positive control consisting of a Trak vial inoculated with serovar L2 strain 434 
(ATCC®VR-902BTM) with MOI = 1 was processed with each batch. 
 
After the 4 day incubation step, one Trak vial per specimen, as well as of the negative and positive 
controls were fixed and stained using the MicroTrak®Chlamydia trachomatis Culture 
Confirmation Test kit (Trinity Biotech) according to manufacturer’s instructions (3.4.2).  Slides 
were examined using a fluorescent microscope with a filter system for fluorescein isothiocyanate 
(FITC) to confirm the presence of chlamydial inclusions.  
If a monolayer infected with a particular specimen was found to be positive for C. trachomatis, 
EBs were harvested from the second Trak vial seeded with that specimen.  This was done by 
removing the CGM, adding 1 ml cold sucrose-phosphate-glutamate (SPG) buffer supplemented 
with 10% FBS and 5 sterile glass beads.  This vial was shaken on a vortex mixer for 1 minute to 
lyse host cells. The resultant chlamydial suspension was collected and inoculated on additional 
McCoy cell monolayers.  Each clinic isolate was sub cultured approximately 3 times until a 
sufficient titre was obtained for use in experiments.  When this was achieved, EB were harvested 
into cold SPG buffer with 10% FBS, cellular debris was pelleted by centrifugation at 200 × g for 
10 minutes at 4°C, and the supernatant containing the organism dispensed into 100µl aliquots 







The Trinity Biotech MicroTrak® Chlamydia trachomatis Culture Confirmation test was used for 




protein (MOMP) which is present in all human serovars of C. trachomatis.  The Microtrak® C. 
trachomatis reagent contains monoclonal antibodies against MOMP labelled with fluorescein 
isothiocyanate.  Once this antibody conjugate binds to the MOMP antigen, C. trachomatis 
inclusion bodies become visible as apple-green fluorescing bodies against the red background of 
the cells counterstained with Evans Blue.  
 
The test was performed according to the manufacturer’s instructions. In brief, excess media was 
removed.  Monolayers were fixed by addition of 1 ml 95% ethanol in distilled water for 10 minutes.  
Following this, the ethanol was removed and the monolayers were rinsed with PB Then 15 µl 
staining solution was added to each well.  This was incubated at 37°C in a humidified chamber for 
30 minutes.   Excess stain was removed and the monolayers rinsed in distilled water with agitation 





3.4.3 Determining the infectious titre 
 
 
One vial of EB suspension of each isolate was thawed and used to prepare10-fold serial dilutions 
in SPG buffer.  These dilutions were used to infect 80-90% confluent McCoy cell monolayers 
grown in a 96-well microtiter plate.  Media was removed from the wells, washed with PBS and 
replaced with 50 µl CGM and 50 µl of chlamydia suspension from each dilution series. This was 
done in triplicate for each dilution series of chlamydia.  Sterile SPG buffer was used as the negative 
control.  The plates were centrifuged at 2500 ×g for 60 minutes at 4°C and then incubated for 1 
hour at 37°C.  Following incubation, media was removed from each well and replaced with 100 




with the Microtrak® C. trachomatis culture confirmation kit reagents and viewed under a 
fluorescent microscope.  
 
The number of inclusions per field of view was enumerated at 100 x magnification and the average 
number of inclusions per field of view was calculated.  Three fields of view were counted for each 
well and three wells were used for the total calculation.  The dilution at which the inclusions were 
counted was the dilution which resulted in 5 - 40 inclusions per field of view. 
 
The infectious titre was then calculated using the following formula: 
 
 
Concentration (IFU/ ml) =      inclusions     x      1’000µl      x      C       x      D 
                                                       n                          V 
 
 
Where: n = number of fields counted 
V = volume of inoculum (µl) 
C = objective lens conversion factor 









3.5. Susceptibility testing 
 
 
The mimimum inhibitory concentration (MIC) of the chlamydia isolates was determined for each 




determine the MIC of C. trachomatis to five concentrations of eight antimicrobial agents.  For 
method 2, the MIC was determined by means of quantitative rPCR detecting 16s rRNA. Both 








The following antimicrobial agents were used:  
 
 Tetracyclines: minocycline, tetracycline and doxycycline 
 Glycycline: tigecycline 
 Macrolides: azithromycin, clarithromycin and erythromycin 
 Fluoroquinolone: ciprofloxacin 
 
The range of concentrations of each antimicrobial agent tested was determined based on the 
published MICs for L2 strain 434 which was used as the susceptible control.  We included the 
MIC plus two 2-fold dilutions above and two 2-fold dilutions below the published MIC. The 









Table 3: Antibiotic concentrations used based on the known MIC for L2 
 




3.5.2 MIC determination by microbroth dilution assay with immunofluorescence 
 
 
McCoy cells (8 × 105 cells) suspended in 100 µl cell culture medium without antibiotics were 
seeded into the wells of flat bottom 96-well tissue culture microtitre plates. These plates were 
incubated at 37°C for 48 hours to yield an 80% confluent monolayer.  
 
The 80% confluent cells in three wells of each 96-well plate were trypsinized and a cell count was 







Tetracycline 2 1 0.5* 0.25 0.125 
 
Walsh et al, 1991 
Minocycline 0.125 0.0625 0.03125* 0.0156 0.0078 Miyashita et al,1996 
Doxycycline 0.125 0.0625 0.03125* 0.0156 0.0078 
Miyashita et al, 
1996 
Tigecycline 0.5 0.25 0.125* 0.0625 0.03125 
Townsend et al, 
2011 
Clarithromycin 0.125 0.0625 0.03125* 0.0156 0.0078 
Miyashita et al, 
1996 
Azithromycin 0.5 0.25 0.125* 0.0625 0.03125 
Miyashita et al, 
1996 
Erythromycin 0.5 0.25 0.125* 0.0625 0.03125 
Miyashita et al, 
1996 
Ciprofloxacin 4 2 1* 0.5 0.25 





of the chlamydial isolates to produce inoculum with an MOI of 1.  Before infection, cell culture 
medium was aspirated from the wells and replaced with 100 μl CGM without antibiotics.  The 50 
µl of the inoculum or the negative control (sterile SPG buffer) was added and the plates centrifuged 
at 2500 x g for 1 h and incubated at 37°C for 1 h.  The antibiotic free media was removed and 
replaced with 150 µl fresh CGM containing appropriate concentrations of the antimicrobial agent 
to be tested (Table 1).  The plates were incubated at 37°C for 2 days.   After this time, the 
monolayers were fixed and stained using the Microtrak® Chlamydia trachomatis culture 
confirmation test as per manufacturer’s instructions (3.4.2).  
Stained monolayers were visualised at 100× magnification using a fluorescent microscope with a 
filter system for FITC (λ = 520 nm).  The lowest concentration of antimicrobial agent which 
resulted in no visible chlamydia inclusions was taken as the MIC. 
 
 
3.5.3MIC determination by detection of chlamydial 16srRNA 
 
 
3.5.3.1 Cell culture 
 
McCoy cells were seeded into the wells of 12-well tissue culture plates at a concentration of 8 x 
105cells per well. After 24 hours of incubation at 37oC , the cells in three wells were trypsinized 
and a cell count was done to calculate the dilution of the chlamydial isolates to add to each well in 
order to achieve a MOI of 1.  Before inoculation, cell culture medium was aspirated from the wells 
and replaced with 1 ml CGM without antibiotics.  Cells were infected in duplicate with C. 
trachomatis US151 suspended in 100 µl SPG.  One hundred microlitres sterile SPG was used as 





The plates were centrifuged at 2500 × g for 1 h and incubated at 37°C for 1 h. Following this, the 
inoculum was removed and replaced with 1ml fresh CGM containing appropriate concentrations 
of each antimicrobial agent.  These cultures were incubated at 37°C for 2 days.  
 
 
3.5.3.2 RNA isolation 
 
After the 48 hour incubation period the CGM with antibiotics was replaced with 2 ml 5M GTC 
lysis buffer per well. The buffer was pipetted up and down five times in order to lyse the cells.    
The cell lysate was transferred to a 15ml centrifuge tube and mixed using a vortex mixer for 2 
minutes.  This was followed by centrifugation at 3000 ×g for 30 mins.  The supernatant was 
removed and the pellet was resuspended in 200µl of GTC lysis solution as mentioned above.  This 
suspension was transferred to a micro-centrifuge tube and centrifuged at 15000 × g for 20 seconds.  
The supernatant was discarded and the pellet re-suspended in 200µl Trisure (Bioline) and 
transferred to another micro-centrifuge tube with silicon microbeads.  This suspension was 
subjected to 4 cycles of the following: mix on a vortex mixer for 2 minutes; incubate on ice for 1 
minute. The suspensions were stored at -70°C until RNA isolation could be completed.  
To complete RNA isolation, the Trisure suspensions were retrieved from the freezer and mixed 
briefly on a vortex mixer.  This was followed by centrifugation at 12,000 × g for 10 min at 4°C.  
The supernatant was transferred to a 2 ml micro centrifuge tube and incubated at room temperature 
for 10 min. Forty µl of cold chloroform (Sigma) was added and the tube was mixed by shaking 
vigorously by hand for 30seconds.  The tube was then incubated at room temperature for 10 




RNA was transferred to another 2 ml micro-centrifuge tube and 100 µl of cold isopropanol 
(Sigma) was added and mixed by inverting the tube three times.  This mixture was incubated at 
room temperature for 15min and then centrifuged at 12,000 × g for 15 min at 4°C.  The supernatant 
was carefully decanted without disturbing the RNA pellet, which was then washed by re-
suspending the pellet in 200µl 75% ethanol (Merck) and centrifugation at 7500 × g for 5min at 
4°C.  The supernatant was again decanted and the pellet was air-dried for 10 minutes then re-
suspended in 14 µl of RNA-secure (Sigma) by 10 cycles of aspiration and release using a pipette.  
This was incubated for 10 min at 60°C and placed on ice.  A nanodrop spectrophotometer 
(Nanodrop 2000c Spectrometer – Thermofisher) was used to quantify RNA concentration and 
determine the purity.  Isolated RNA was stored at -70°C until cDNA could be synthesised.   
 
3.5.3.3 cDNA Synthesis 
 
cDNA synthesis was carried out using the ABI high capacity cDNA synthesis kit according to 
manufacturer’s instructions.  Individual PCR tubes were used, to which 10µl of 2 × RT mix was 
added together with 2000 ng of RNA which was then suspended in 14µl RNA-secure.  Tubes were 
sealed and briefly centrifuged to spin down the contents and eliminate air bubbles.  The tubes were 
then loaded into the thermal cycler (Gene amp 9700 Life Technologies) and subjected to the 
following cycle conditions:  
Step 1: 25°C for 10 min 
Step 2: 37°C for 120min 
Step 3: 85°C for 5sec 





Tubes were stored at 2-6°C. 
 
3.5.3.4 Real Time PCR 
 
Real time PCR was carried out using the Taqman gene expression master mix.   This was made up 
according to Goldschmidt et al, 2006. The following primers and probes were used:  
Forward primer: (5´TCGAGAATCTTTCGCAATCGAC) 
Reverse primer: (5´CGCCCTTTACGCCCAATAAA) 
Probe: (FAM-AAGTCTGACGAAGCGACGCCGC) 
A total of 22.5µl of the mastermix consisting of  AmpliTaq Gold® DNA Polymerase (Ultra Pure), 
Uracil-DNA glycosylase, dNTPs (with dUTP), ROX™ Passive Reference, and optimized buffer 
components was pipetted into each well, followed by the addition of 2.5µl cDNA (diluted sample) 
or 2.5µl nuclease free water for the template free control.  Plates were centrifuged at 250 × rpm 
for 20 minutes at 25°C before loaded them into the real time machine (Applied Biosystems 7500 
Real time PCR system) and subjected to the following cycle conditions:  
  2 minutes at 50°C 
  10 minutes at 95°C 




Interpretation of PCR results were achieved using the Comparitive CT Method.  This method 






















CHAPTER 4 – RESULTS 
 
Specimens were collected from 967 patients that attended one of the two clinics (3.1).  Of these, 
622 (64.3%) were seen at the Boom Street Clinic in Pietermaritzburg and 345 (35.7%) at the 
Umlazi D Clinic in Durban.  Male urethritis syndrome was diagnosed in 531 (54.9%) patients and 
411 (42.5%) had female discharge syndrome. All specimens were screened for C. trachomatis 
using the BD ProbeTecTM ET CT/GC DNA Amplification Assay and C. trachomatis DNA was 
detected in 65 (6.7%) specimens.  These 65 specimens were cultured, but only four (6%) grew.  
These four C. trachomatis isolates, designated SAR28, SAR90, SAR175 and SAR286, were sub-
cultured until a sufficient titre had been reached for use in susceptibility tests. The number of 
subcultures to achieve this varied between 3 and 5.  All four were collected from patients who 
presented at the Boom Street Clinic in Pietermaritzburg.  Three of these patients were female and 
one was male.  
 
4.1 Minimum Inhibitory Concentration (MIC) determination by immunofluorescence 
 
MICs were determined for total of 11 C. trachomatis isolates using clinically relevant 
antimicrobial agents.  Clinical isolates 28, 90, 175 and 286 were obtained from male and female 
participants presenting at the Pietermaritzburg Boom Street Clinic.  These strains were isolated 




Clinical isolate E was also used which was isolated in 1996 by Maleka and coworkers. This strain 
belongs to the OG biovar and was obtained from a male patient presenting with urethritis at Prince 
Cyril Zulu Communicable Diseases Clinic in Durban. 
Three additional chlamydia isolates, US151, US162 and US197 were also used in this study. These 
isolates were grown by Joubert BC, 2009 from ulcer specimens retrieved from patients at the 
Prince Cyril Zulu Communicable Diseases Clinic in Durban.  All three were L2 serovars. 
The remaining three organisms used were LGV strains from the ATCC collection. These were L1 
440 (ATCC® VR-901B®), L2 434 (ATCC® VR-902B™) and L3 404 (ATCC® VR-903B™). 
These LGV strains were isolated by Schachter et al, 1969 from military servicemen and seamen 
who presented with typical LGV symptoms. L2 434 (ATCC® VR-902B™) served as the reference 
strain for MIC determination because its MIC values have been published by others (Miyashita et 
al, 1996, Walsh et al, 1991 and Townsend et al, 2011) 
Table 4 summarises the results. All 11 C. trachomatis isolates were inhibited by all the 
antimicrobial agents tested. For tetracycline, minocycline and erythromycin the MIC was the same 
for all isolates tested.  These were ≤ 0.125 mg/L, 0.125 mg/L and 0.125 mg/L respectively.  There 
was little variation in the MICs of the other antimicrobial agents.  For doxycycline all isolates had 
an MIC of 0.0625 mg/L with the exception of SAR175 which had an MIC of 0.03125 mg/L.  For 
clarithromycin all isolates had an MIC of < 0.0078 mg/L except L2 strain 434 and SAR 90 which 
both had an MIC of 0.0156 mg/L.  For azithromycin all isolates had an MIC of 0.25 mg/L except 
US197, SAR175 and the serovar E clinical isolate. These were 0.125, 0.125 and 0.5 mg/L 
respectively.  For ciprofloxacin all isolates had an MIC of 1 mg/L except US197 which had an 




strains, the serovar E clinical isolate, and SAR175 all had an MIC ≤ 0.03125 mg/L.  US151, 
US162, SAR28 and SAR90 had an MIC of 0.0625 mg/L, while US197 and SAR286 had an MIC 
of 0.125 mg/L.   
 
 









Isolate Tet Min Dox Tige Clarith Azith Eryth Cipro 
SAR28 ≤ 0.125 0.125 0.0625 0.0625 ≤ 0.0078 0.25 0.125 1 
SAR90 ≤ 0.125 0.125 0.0625 0.0625 0.0156 0.25 0.125 1 
SAR175 ≤ 0.125 0.125 0.03125 ≤0.03125 ≤ 0.0078 0.125 0.125 1 
SAR286 ≤ 0.125 0.125 0.0625 0.125 ≤ 0.0078 0.25 0.125 1 
E ≤ 0.125 0.125 0.0625 ≤0.03125 ≤ 0.0078 0.5 0.125 1 
US151 ≤ 0.125 0.125 0.0625 0.0625 ≤ 0.0078 0.25 0.125 1 
US162 ≤ 0.125 0.125 0.0625 0.0625 ≤ 0.0078 0.25 0.125 1 
US197 ≤ 0.125 0.125 0.0625 0.125 ≤ 0.0078 0.125 0.125 0.5 
L1 440 ≤ 0.125 0.125 0.0625 ≤0.03125 ≤ 0.0078 0.25 0.125 1 
L2 434 ≤ 0.125 0.125 0.0625 ≤0.03125 0.0156 0.25 0.125 1 
L3 404 ≤ 0.125 0.125 0.0625 ≤0.03125 ≤ 0.0078 0.25 0.125 1 
Tet, tetracycline; Min, minocycline; Dox, doxycycline; Tige, tigecycline; Clarith, clarithromycin; 






The highest magnification at which the stained monolayers could be read with the fluorescent 
microscope at the bottom of the wells in the 96-well plates was 200 ×.  This was because we stained 
and visualised the monolayer directly in the 96-well plates and the hight of the plates left no space 
for the objective lenses with higher magnification.  To confirm whether or not the antimicrobial 
agents used had merely slowed the growth of the organism resulting in the formation of tiny 
inclusions which could not be visualised at a low magnification, we selected one isolate (US151) 
and repeated each susceptibility test on McCoy cell monolayers grown on glass coverslips inserted 
in a 24-well plate.  The cell monolayers were stained directly in the wells, thereafter the glass cover 
slips were removed and mounted onto glass slides.  This enabled the cell monolayers to be viewed 
at 1000 × magnification for visualisation of tiny inclusions which may not have been seen at the 
lower magnification.   
Figures 1 A-D compare the images captured at 200 × magnification with those captured at 1000 × 
magnification for US151 when exposed to each antimicrobial agent.  When comparing these 
images, no inclusions were detected at any of the two magnifications for any of the antimicrobial 
agents.  Because viewing the cells under a higher magnification yielded the same results as the 
lower magnification, visualisation and interpretation using 200 × magnification is deemed 









Figure 1A-D (pages 39 to 42overleaf).  Fluorescent micrographs of McCoy cell 
monolayers.  Cells were infected with Chlamydia trachomatis isolate number US 151 by 
centrifugation, treated with different concentrations of clinically relevant antimicrobial agents and 
stained with the MicroTrak C. trachomatis culture confirmation kit for the detection of green 
chlamydial inclusions which indicate growth of the organism. Images were captured at 200 × and 
1000 × magnification.  Antimicrobial agents included (A) tetracyclines (tetracycline, minocycline, 
doxycycline), (B) a glycycline (tigecycline), (C) a fluoroquinolone (ciprofloxacin) and (D) 
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4.2 MIC determination by real time PCR 
 
The absence of resistance in the IF experiments informed the decision to test only one isolate by 
real time PCR to develop and assess the methodology and to show proof of principle.  
A total of two runs were completed and the results summarized in Table 5.  “Detected” (D) 
represents more than three wells with a positive reaction by real time PCR.  “Not detected” (ND) 
represents less than 3 positive wells by real time PCR.  “Undetermined” (U) represents samples 
which produced 3 positive and 3 negative wells by real time PCR.  The minimum inhibitory 
concentration was taken as the lowest concentration of an antimicrobial agent with the result “ND”. 
For erythromycin, clarithromycin, azithromycin, ciprofloxacin and tigecycline the MIC was 0.125, 
0.0156, 0.125, 1 and 0.5 mg/L respectively.  For minocycline chlamydial cDNA was detected after 
48 hour of exposure to all concentrations of the antimicrobial agent used in this study.  For 
tetracycline and doxycycline chlamydial cDNA was not detected after 48 hours exposure to any 








MICs were determined by PCR twice in triplicate.  After these two runs it was evident that the 
MIC determination by immunofluorescence was more reproducible than that by real time PCR 
so the third planned run was not performed.  The MICs of US151 as determined by 
immunofluorescence are compared with those determined by real time PCR in Table 6. 
The real time PCR results show different MICs for all of the antimicrobials used when compared 
to immunofluorescence.  The discrepancies were no more than two 2-fold dilutions different for 
six of the antimicrobial agents.  The exceptions are doxycycline and tigecycline.  The MIC for 
doxycycline against this isolate was at least 4-fold lower when determined by real time PCR.  The 
Table 5: Detection of C. trachomatis cDNA (isolate US151) using real time PCR following 
culture of the organism in the presence of antimicrobial agents 










2 1 0.5 0.25 0.125 
ND ND ND ND ND 
Minocycline 
0.125 0.0625 0.03125 0.0156 0.0078 
D D D D D 
Doxycycline 
0.125 0.0625 0.031 0.0126 0.0078 







0.5 0.25 0.125 0.0625 0.03125 








0.125 0.0625 0.03125 0.0156 0.0078 
ND ND U ND U 
Azithromycin 
0.5 0.25 0.125 0.062 0.03125 
ND ND ND U U 
Erythromycin 
0.5 0.25 0.125 0.0625 0.031 










4 2 1 0.5 0.25 
ND ND ND U D 








Table 6. Minimum Inhibitory Concentrations (MIC) of Chlamydia trachomatis isolate 







Method Tet Min Dox Eryth Clarith Azith Cipro Tige 
IF 0.125 0.125 0.0625 0.125 ≤0.0078 0.25 1 0.0625 
PCR ≤0.125 >0.125 ≤0.0078 0.0625 0.03125 0.0625 0.5 0.5 
Tet, tetracycline; Min, minocycline; Dox, doxycycline; Eryth, erythromycin; Clarith, 
clarithromycin; Azith, azithromycin; Cipro, ciprofloxacin; Tige, tigecycline; IF, 
















CHAPTER 5– DISCUSSION 
 
Resistance to anti-microbial drugs has become a major problem worldwide and affects pathogens 
that cause infections in all parts of the human body. The organisms that cause sexually transmitted 
infections (STIs) are by nature fastidious and therefore, drug resistance profiles are only available 
for those bacterial species that can be grown in cell-free culture media. This includes Neisseria 
gonorrhoeae and Haemophilus ducreyi. Information on drug resistance in organisms that cannot 
readily be grown is scanty at most. These include Treponema pallidum, Klebsiella granulomatis 
and Chlamydia trachomatis.  
The development of bacterial resistance to antimicrobial agents included in the syndromic 
management regime is a major concern for the treatment of STDs (Mundayet al, 1995).  If a 
particular pathogen in a given population develops resistance to the antimicrobial agent which 
covers that pathogen in the syndromic management regime, then that antimicrobial agent needs to 
be substituted for another suitable antimicrobial agent. The antimicrobial agent being used must 
cover at least 95% of isolates of that species in the geographical area concerned (WHO, 2003).  
Therefore periodic susceptibility testing of the pathogens which cause STDs is required in order 
for syndromic management to be effective.  The aim of this study was to determine if C. 
trachomatis isolates from patients in KwaZulu-Natal province of South Africa have developed 
resistance to the drugs which cover this organism in the syndromic management regime, and if so, 
to determine which antimicrobial agent would be a suitable alternative.  The antimicrobial agents 





Specimens were collected from two different clinics in two major cities in the province, the Boom 
Street Clinic in Pietermaritzburg and the Umlazi D Clinic in Durban. In an initial trial run, the 
HeLa cell line was used, but no organisms were isolated using this cell line.  This may have been 
due to shorter incubation times used.  We then substituted this for the McCoy cell line and 
increased the incubation time from 48 to 96 hours.  Using this approach, from the 967 specimens 
collected across both sites, 65 were positive in the C. trachomatis NAAT but only 4 isolates could 
be cultured. Since this is a low success rate, these cultured strains are not very representative.  
Various factors such as pH, temperature and polarity of the cell types can influence growth of an 
organism (Suchland et al, 2003).  McCoy cells are known to produce a higher number of 
chlamydial inclusions at temperatures of 33-35ºC as compared to lower temperatures of 20-25 ºC 
during centrifugation (Rota, 1980).   
The susceptibility tests were performed with local 8 clinical isolates and 3 strains from the ATCC 
collection. One of the latter (L2 434 ATCC® VR-902B™) was used as control since MICs for this 
strain have been published (Miyashita et al, 1997 and Walsh et al, 1987). The other two LGV 
serovars used were L1 strain 440 (ATCC® VR-901B® and L3 strain 404 (ATCC® VR-903B™).  
These LGV strains were isolated by Schachter et al, 1969 from military servicemen and seamen 
who presented with typical LGV symptoms.  None of the current isolates nor the LGV clinical 
isolates or the discharge isolate from 1996 were resistant to any of the antibiotics tested. All MICs 
were below the breakpoints for resistance independent of whether the EUCAST or CLSI reference 
values for other tissue infections were applied.  
Due to its obligate intracellular lifecycle, susceptibility testing of C. trachomatis is technically 
challenging and there is no single standardized technique.  All methods described to date involve 




interest at a suitable concentration, followed by a method to determine whether or not the 
bacterium multiplied in the presence of the antimicrobial agent. This could include 
immunofluorescence or a quantitative nucleic acid amplification test, however NAATs are 
required for screening and diagnosis rather than susceptibility testing (Cross et al, 1999).  
Immunofluorescence is an antibody detection based assay and there are two types namely, direct 
and indirect immunofluorescence (Magro et al, 2003).  Direct immunofluorescence involves the 
use of an antibody conjugated with a fluorochrome and directed against the antigen.  Indirect 
immunofluorescence involves the use of an additional antibody conjugated with a fluorochrome 
which binds to the Fc portion of the first antibody (Magro et al, 2003).  Immunofluorescence based 
detection methods detect the presence of chlamydia inclusion bodies by visualizing these on 
stained slides with a fluorescent microscope (Stamm, 2000).   
 
This study used a commercially available direct immunofluorescence kit in the 96 well plates used 
and the presence or absence of inclusions was used as an indicator for growth of the organism. To 
show proof of principle, real time PCR was applied on one isolate. We did not perform this 
technique on the remaining 10 organisms because of cost. Real time reversed transcriptase PCR 
was used since it detects RNA of viable organisms only.   
 
Immunoflourescent experiments have shown a decrease in the size and number of chlamydial 
inclusions with increasing concentration of antimicrobial agent.  For some strains of chlamydia, 
the lowest concentration of antimicrobial agents used was effective in preventing growth of the 




minocycline shared the same MIC for all chlamydia strains, whereas doxycycline MIC (0.0625 
and 0.03125) was one dilution lower than tetracycline and minocycline.  
The MICs for macrolides were all different.  Clarithromycin has the lowest MICs whereas the 
MICs for azithromycin and erythromycin are slightly higher for all chlamdia isolates but in the 
susceptible range.  The MIC for all strains exposed to ciprofloxacin was the same except for one 
ulcer sample US197 (0.5), therefore this antimicrobial agent has the same effect on all the 
chlamydia isolates tested since the MIC of US197 was lower than the others.    Ciprofloxacin has 
the highest MIC values as compared to all other antibiotics used.  The use of tigecycyline showed 
a variety of MIC values.  The historical LGV isolates have the lowest MIC for tigecycline, while 
the local ulcer samples and discharge isolates have a higher MIC.  Tigecycline has the widest range 
of MIC values when compared to all other antibiotics tested.   
When comparing the reference strain L2 434 to the MIC values obtained, the values do not differ 
significantly and are either a dilution series higher or below the published MICs.  There are not 
enough published data on MICs for the different serovars of chlamydia.  Data was available for 
serovar E, and when comparing the published data to the values obtained, azithromycin has a 
twofold higher MIC and a threefold higher MIC with regards to Minocycline as compared to the 
published MIC.  Other MICs published for serovar E show no significant difference from the data 
obtained in this study.   
The additional immunoflourescence experiment which was visualized at 1000 × magnification 
(US151 only) (Figure 1A-D) confirmed that the MIC values determined at 200 × magnification 
were correct.  This experiment was performed in the same manner as the other 




24 well plate instead of a 96 well plate, the cells were grown on glass coverslips which were stained 
in the same manner as the 96 well plate experiment but the glass slides were removed from the 24 
well plate, mounted on glass microscope slides and viewed under 1000 × magnification instead of 
200 × magnification.  The reason for this confirmation experiment was to rule out the possibility 
of the antimicrobial agents slowing the growth of C. trachomatis to a point where inclusions were 
still present, but too small to be identified at 200 × magnification. Since the MIC values for US151 
were the same in both the immunofluorescence susceptibility test visualized at high magnification 
and that visualized at low magnification.  The MIC values obtained at low magnification for the 
other isolates were taken to be correct.  
MICs of the seven antimicrobial agents were also determined for one clinical isolate (US151) using 
real time PCR.  For this assay RNA was extracted, converted to cDNA and detected using a real 
time PCR assay. However, in our hands the real time PCR was not well reproducible between the 
two duplicate runs and there were numerous discrepancies for the values obtained with 
immunofluorescence.  For all seven of the antimicrobial agents tested, the MIC value was different 
for the two methods.   In the case of minocycline, clarithromycin and tigecycline the MICs were 
lower when determined by immunofluorescence than real time PCR, but with all other 
antimicrobial agents the MIC was higher when determined by immunofluorescence.  However, 
the difference between the MIC values determined with either method only exceed two dilution 
factors for two antimicrobial agents: doxycycline and tigecycline.  The MIC for doxycycline 
against US151 was more than three-fold higher when determined by immunofluorescence instead 
of real time PCR, but the MIC for tigecycline was three-fold lower when determined by 
immunofluorescence instead of real time PCR.  Immunoflourescence is a rather subjective assay 




difficulty in reading the end point.  The organism may be present as elementary bodies which are 
difficult to see under the microscope, however real time PCR is capable of detecting these 
organisms via RNA detection.   
In a previous study Cross et al (1999) performed susceptibility tests on C. trachomatis and 
compared the results obtained using immunofluorescence with PCR-based methods (Cross et al, 
1999). These authors utilized 16 C. trachomatis isolates, exposed to 8 antimicrobial agents in 
triplicate.  They reported a discrepancy in the MIC values obtained by immunofluorescence versus 
those obtained by PCR, but the MIC values determined using PCR were consistently higher than 
those obtained using immunofluorescence ranging from 1.6-fold higher to ≥195-fold higher.     
In our hands immunofluorescence was more reproducible than real time PCR and clear MIC values 
were determined using this method.  MIC determination using real time PCR was planned to be 
performed in triplicate.  Due to significant inter-test and intra-test variation, only two runs were 
performed.  A possible reason for the poor reproducibility may be the low copy number of 
chlamydial RNA as a result of the fragile RNA being easily degraded.  When isolating RNA, both 
host RNA and chlamydial RNA were isolated simultaneously due to the obligate intracellular 
nature of the bacterium.  The starting concentration of RNA was determined using a Nanodrop 
spectrophotometer and a standardized amount was used for the cDNA conversion, however, this 
amount would have included both host and bacterial RNA.  Although a C. trachomatis specific 
RNA sequence was used for detection in the PCR-based assay, we are uncertain how much 
chlamydia RNA was used for the cDNA conversion and this would have likely varied depending 




A limitation of this study is the small sample size.  Only four fresh clinical isolates were isolated 
as part of this study.  Four stored clinical isolates which were collected as part of previous studies 
in KZN plus three commercially available ATCC strains were included to increase the sample size.  
If more clinical isolates had been cultured, we would have had a greater chance of detecting 
resistance to any of the antimicrobial agents included if there were resistant organisms circulating 
in the population.  The collection and processing of clinical specimens is a labour intensive and 
time consuming process with a low culture positivity rate in our hands making it financially not 
feasible to increase the duration of specimen collection to increase the sample size.  
In conclusion all the C. trachomatis isolates and historical ATCC strains tested in this study are 
sensitive to all the antimicrobial agents used, including azithromycin which is currently included 
in the syndromic management regime for the treatment of C. trachomatis. The most effective 
antimicrobial with the lowest MIC value is clarithromycin, followed by tigecycline which has the 
second lowest MIC.  The tetracycline group of antibiotics also have MIC values lower than 
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APPENDIX A – Antimicrobial agents and Media Preparation 
 
Antimicrobial Agent Preparation:  
 
Antimicrobial agents were prepared according to table A1 below.  These were stored in 1ml 
aliquots until use.  When needed, a vial of stock solution was used and 1:2 serial dilutions were 
prepared in CGM to acquire the desired concentration needed for each antimicrobial agent 
according to published MICs for reference strain L2 434 (Table 1). 
 
 













Tetracycline 95% ethanol 98 0.0103 10 1 -20 
Minocycline dH20 100 0.01 10 1 -20 
Doxycycline dH20 98 0.0103 10 1 -20 
Tigecycline DMSO 98 0.0103 10 1 -20 
Azithromycin DMSO 95 0.01075 10 1 -20 
Clarithromycin DMSO 98 0.0103 10 1 -20 
Erythromycin dH20 98 0.0205 10 2 -20 












CGM for infection: 
102 ml EMEM with NEAA 
12 ml FBS 
6 ml 20 × glucose 
1.2 ml Hepes 
12 µl cyclohexamide 
 
Cyclohexamide 
Dissolved 0.0196 g cyclohexamide (98%) in 19.2 ml distilled water.  
Stored in 1 ml aliquots at -20°C. 
 





50 µl gentamycin 
50 µl amphotericin B 
 
20 × glucose 
Dissolved 5.28g glucose (anhydrous) in 60 ml EMEM 






60 ml EMEM 
20 ml FBS 
20 ml DMSO 
 Filter sterilized solution.  Stored in 10 ml aliquots at -20°C.  
 
GTC Lysing Solution (100ml): 
60g 5M guanidinum thiocyanate  
0.5g 0.5% sodium-N-lauryl sarcosine   
1g 26mM tri-sodium citrate 
0.7ml 0.1M 2-mercaptoethanol 
 





Dissolved the above reagents in 400 ml autoclaved distilled water 
Adjusted pH using 4M NaOH (7.4-7.6) 
Brought volume up to 500 ml using autoclaved distilled water 
Filter sterilized through 0.22 µm filter 












Tables B1-9 below show results from immunoflourescence experiments.  Results are shown for 
each Chlamydia isolate exposed to the different antimicrobials tested.  
 
Real Time PCR 
Results from PCR experiments can be seen in tables B10-13 below.  The tables represent 
Chlamydia isolate US151 which was exposed to the antimicrobial agents for PCR experiments.  






















 Azith Eryth Clarith Tet Doxy Mino Cipro Tige 
E 0.25 0.125 MIC ≤conc used 
MIC≤conc used 
0.0625 0.125 1 0.03125 
L1 0.25 0.125 MIC ≤conc used 
MIC≤conc used 
0.0625 0.125 1 0.03125 
L2 0.25 0.125 0.0625 
MIC≤conc used 
0.0625 0.125 1 0.03125 
L3 0.25 0.125 
MIC≤conc used MIC≤conc used 
0.0625 0.125 1 0.03125 
US151 0.25 0.125 
MIC≤conc used MIC≤conc used 
0.0625 0.125 1 0.0625 
US162 0.25 0.125 
MIC≤conc used MIC≤conc used 
0.0625 0.125 1 0.0625 
US197 0.125 0.125 
MIC≤conc used MIC≤conc used 
0.0625 0.125 0.5 0.125 
28 0.25 0.125 
MIC≤conc used MIC≤conc used 
0.0625 0.125 1 0.0625 
90 0.25 0.125 0.0625 
MIC≤conc used 
0.0625 0.125 1 0.0625 
175 0.125 0.125 
MIC≤conc used MIC≤conc used 
0.03125 0.125 1 
MIC≤conc 
used 
286 0.25 0.125 
MIC≤conc used MIC≤conc used 






Table B2: Tetracycline susceptibility 
 2 1 0.5 0.25 0.125 No Antibiotic 
E No Growth No Growth No Growth No Growth No Growth Growth 
L1 No Growth No Growth No Growth No Growth No Growth Growth 
L2 No Growth No Growth No Growth No Growth No Growth Growth 
L3 No Growth No Growth No Growth No Growth No Growth Growth 
US151 No Growth No Growth No Growth No Growth No Growth Growth 
US162 No Growth No Growth No Growth No Growth No Growth Growth 
US197 No Growth No Growth No Growth No Growth No Growth Growth 
28 No Growth No Growth No Growth No Growth No Growth Growth 
90 No Growth No Growth No Growth No Growth No Growth Growth 
175 No Growth No Growth No Growth No Growth No Growth Growth 





Table B3: Minocycline Susceptibility 
 0.125 0.0625 0.03125 0.0156 0.0078 No Antibiotic 
E No Growth Growth Growth Growth Growth Growth 
L1 No Growth Growth Growth Growth Growth Growth 
L2 No Growth Growth Growth Growth Growth Growth 
L3 No Growth Growth Growth Growth Growth Growth 
US151 No Growth Growth Growth Growth Growth Growth 
US162 No Growth Growth Growth Growth Growth Growth 
US197 No Growth Growth Growth Growth Growth Growth 
28 No Growth Growth Growth Growth Growth Growth 
90 No Growth Growth Growth Growth Growth Growth 
175 No Growth Growth Growth Growth Growth Growth 









Table B4: Doxycycline Susceptibility 
 0.125 0.0625 0.03125 0.0156 0.0078 No Antibiotic 
E No Growth No Growth Growth Growth Growth Growth 
L1 No Growth No Growth Growth Growth Growth Growth 
L2 No Growth No Growth Growth Growth Growth Growth 
L3 No Growth No Growth Growth Growth Growth Growth 
US151 No Growth No Growth Growth Growth Growth Growth 
US162 No Growth No Growth Growth Growth Growth Growth 
US197 No Growth No Growth Growth Growth Growth Growth 
28 No Growth No Growth Growth Growth Growth Growth 
90 No Growth No Growth Growth Growth Growth Growth 
175 No Growth No Growth No Growth Growth Growth Growth 





Table B5: Tigecycline Susceptibility 
 0.5 0.25 0.125 0.0625 0.03125 
No 
Antibiotic 
E No Growth No Growth No Growth No Growth No Growth Growth 
L1 No Growth No Growth No Growth No Growth No Growth Growth 
L2 No Growth No Growth No Growth No Growth No Growth Growth 
L3 No Growth No Growth No Growth No Growth No Growth Growth 
US151 No Growth No Growth No Growth No Growth Growth Growth 
US162 No Growth No Growth No Growth No Growth Growth Growth 
US197 No Growth No Growth No Growth Growth Growth Growth 
28 No Growth No Growth No Growth No Growth Growth Growth 
90 No Growth No Growth No Growth No Growth Growth Growth 
175 No Growth No Growth No Growth No Growth No Growth Growth 








Table B6: Clarithromycin Susceptibility 
 0.125 0.0625 0.03125 0.0156 0.0078 No Antibiotic 
E No Growth No Growth No Growth No Growth No Growth Growth 
L1 No Growth No Growth No Growth No Growth No Growth Growth 
L2 No Growth No Growth No Growth No Growth Growth Growth 
L3 No Growth No Growth No Growth No Growth No Growth Growth 
US151 No Growth No Growth No Growth No Growth No Growth Growth 
US162 No Growth No Growth No Growth No Growth No Growth Growth 
US197 No Growth No Growth No Growth No Growth No Growth Growth 
28 No Growth No Growth No Growth No Growth No Growth Growth 
90 No Growth No Growth No Growth No Growth Growth Growth 
175 No Growth No Growth No Growth No Growth No Growth Growth 





Table B7: Azithromycin Susceptibility 
  0.5 0.25 0.125 0.0625 0.03125 No Antibiotic 
E No Growth Growth Growth Growth Growth Growth 
L1 No Growth No Growth Growth Growth Growth Growth 
L2 No Growth No Growth Growth Growth Growth Growth 
L3 No Growth No Growth Growth Growth Growth Growth 
US151 No Growth No Growth Growth Growth Growth Growth 
US162 No Growth No Growth Growth Growth Growth Growth 
US197 No Growth No Growth No Growth Growth Growth Growth 
28 No Growth No Growth Growth Growth Growth Growth 
90 No Growth No Growth Growth Growth Growth Growth 
175 No Growth No Growth No Growth Growth Growth Growth 








Table B8: Erythromycin Susceptibility 
  0.5 0.25 0.125 0.0625 0.03125 No Antibiotic 
E No Growth No Growth No Growth Growth Growth Growth 
L1 No Growth No Growth No Growth Growth Growth Growth 
L2 No Growth No Growth No Growth Growth Growth Growth 
L3 No Growth No Growth No Growth Growth Growth Growth 
US151 No Growth No Growth No Growth Growth Growth Growth 
US162 No Growth No Growth No Growth Growth Growth Growth 
US197 No Growth No Growth No Growth Growth Growth Growth 
28 No Growth No Growth No Growth Growth Growth Growth 
90 No Growth No Growth No Growth Growth Growth Growth 
175 No Growth No Growth No Growth Growth Growth Growth 






Table B9: Ciprofloxacin Susceptibility 
 4 2 1 0.5 0.25 No Antibiotic 
E No Growth No Growth No Growth Growth Growth Growth 
L1 No Growth No Growth No Growth Growth Growth Growth 
L2 No Growth No Growth No Growth Growth Growth Growth 
L3 No Growth No Growth No Growth Growth Growth Growth 
US151 No Growth No Growth No Growth Growth Growth Growth 
US162 No Growth No Growth No Growth Growth Growth Growth 
US197 No Growth No Growth No Growth No Growth Growth Growth 
28 No Growth No Growth No Growth Growth Growth Growth 
90 No Growth No Growth No Growth Growth Growth Growth 
175 No Growth No Growth No Growth Growth Growth Growth 













 Tetracycline Minocycline Doxycycline 





























































































































































































































0.5 0.25 0.125 0.0625 0.03125 
Run 1 40.87 37.79 37.72 40.54 38.47 
Run 1 ND 40.27 37.63 39.19 40.22 
Run 1 ND 40.8 38.11 44.26 40.72 
Run 2 ND ND 37.53 36.81 37.15 
Run 2 ND ND 35.18 36.31 ND 










 Erythromycin Clarithromycin Azithromycin 





























































































































































































































4 2 1 0.5 0.25 
Run 1 ND ND ND 40.95 36.59 
Run 1 ND ND 40.42 40.23 37.88 
Run 1 ND ND 39.89 39.92 38.35 
Run 2 15.56 ND ND ND 37.79 
Run 2 6.61 6.77 ND ND ND 




APPENDIX C – Immunofluorescent Images 
 
Figure C1-24 (pages 84 to 107 overleaf).  Fluorescent micrographs of McCoy cell 
monolayers.  Cells were infected with Chlamydia trachomatis isolates by centrifugation, treated 
with different concentrations of clinically relevant antimicrobial agents and stained with the 
MicroTrak C. trachomatis culture confirmation kit for the detection of green chlamydial inclusions 
which indicate growth of the organism. Images were captured at 100 × 
magnification.  Antimicrobial agents included (C1-9) tetracyclines (tetracycline, minocycline, 
doxycycline), (C10-12) a glycycline (tigecycline), (C13-21) macrolides (clarithromycin, 
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